Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Kezar Life Sciences, Inc. (KZR) had Consolidated Net Income/Loss of $-83.74M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-83.74M |
|
-- |
|
-- |
|
$90.61M |
|
$-90.61M |
|
$6.87M |
|
$-83.74M |
|
$-83.74M |
|
$-83.74M |
|
$-83.74M |
|
|
Consolidated Net Income/Loss |
$-83.74M |
$-83.74M |
|
$-90.61M |
|
$-94.35M |
|
7.29M |
|
7.29M |
|
$-11.49 |
|
$-11.49 |
|
| Balance Sheet Financials | |
$137.49M |
|
$2.89M |
|
$7.19M |
|
$144.68M |
|
$20.33M |
|
$5.11M |
|
$7.44M |
|
$27.77M |
|
$116.92M |
|
$116.92M |
|
$116.92M |
|
7.30M |
|
| Cash Flow Statement Financials | |
$-74.21M |
|
$80.43M |
|
$0.10M |
|
$35.49M |
|
$41.75M |
|
$6.26M |
|
$13.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.76 |
|
-- |
|
-- |
|
0.04 |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-74.24M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-71.62% |
|
-71.62% |
|
-57.88% |
|
-68.62% |
|
$16.01 |
|
$-10.18 |
|
$-10.18 |
|